Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gynecology | Oncology | Pathology | Conference News

Back to Journal Articles

SABCS: Chemo Plus Herceptin Found to Improve Outcomes

Last Updated: December 14, 2009.

 

Concurrent therapy improves disease-free survival in women with HER2+ breast cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In women who undergo surgery to treat Stage I to III invasive HER2+ breast cancer, postoperative treatment with concurrent chemotherapy and Herceptin significantly improves disease-free survival, according to research presented at the San Antonio Breast Cancer Symposium, held from Dec. 9 to 13.

MONDAY, Dec. 14 (HealthDay News) -- In women who undergo surgery to treat Stage I to III invasive HER2+ breast cancer, postoperative treatment with concurrent chemotherapy and Herceptin significantly improves disease-free survival, according to research presented at the San Antonio Breast Cancer Symposium, held from Dec. 9 to 13.

Edith A. Perez, M.D., of the Mayo Clinic in Jacksonville, Fla., and colleagues from the North Central Cancer Treatment Group study compared outcomes in 1,087 women who received chemotherapy alone and 1,097 women who received chemotherapy followed by Herceptin. They also compared outcomes in 954 women who received chemotherapy followed by Herceptin, and 949 women who received concurrent chemotherapy and Herceptin.

In the first comparison, the researchers found that the five-year disease-free survival rate was significantly higher in women who received chemotherapy followed by Herceptin than in those who received chemotherapy alone (80 versus 72 percent). In the second comparison, they found that the five-year disease-free survival rate was higher in women who received concurrent chemotherapy and Herceptin than in those who received chemotherapy followed by Herceptin (84 versus 80 percent).

"The results of this trial have been eagerly awaited in the United States and in many nations as this is the only trial developed to define the optimal way to incorporate Herceptin in the context of adjuvant chemotherapy," Perez said in a statement. "The goal was to decrease the risk of cancer recurrence, and we have shown that concurrent use is the best way to achieve that. This could mean that up to 10,000 women around the world each year may have a better outcome if Herceptin is used along with chemotherapy."

This study was partially supported by Genentech.

Symposium Information

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: American Society of Hematology, Dec. 5-8, 2009 Next: Racial Disparities Seen in Breast Cancer Radiotherapy

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.